A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses

Immunology Letters

Volumn 122, Issue 1, 2009, Pages 44-51

  Gabitzsch, Elizabeth S ^a   Xu, Younong ^a   Yoshida, Lois H ^a   Balint, Joseph ^a   Gayle, Richard B ^a   Amalfitano, Andrea ^b   Jones, Frank R ^a  

^a Etubics Corporation   (United States)

^b Michigan State University ^*  (United States)

Author keywords

Adenovirus 5; Cell mediated immunity; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIGENS, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE DELETION; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 59649119374     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.11.003     Document Type: Article

References (48)

1. Gómez-Román V.R., and Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev 5 (2003) 178-185
2. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
3. Appaiahgari M.B., Saini M., Rauthan M., Jyoti, and Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 8 (2006) 92-104
4. Barratt-Boyes S.M., Soloff A.C., Gao W., Nwanegbo E., Liu X., Rajakumar P.A., et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J Gen Virol 87 (2006) 139-149
5. Cantanzaro A.T., Koup R.A., Roederrer M., Bailer R.T., Enama M.E., Moodic Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 12 (2006) 1638-1649
6. Tims T., Briggs D.J., Davis R.D., Xiang Z., Ertl H.C., and Fu Z.F. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine 18 (2000) 2804-2807
7. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76 (2002) 2667-2675
8. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. JEM 205 (2008) 7-11
9. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81 12 (2007) 6594-6604
10. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.O., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
11. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 (2003) 6305-6313
12. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 (2003) 8729-8735
13. Thorner A.R., Lemckert A.A., Goudsmit J., Lynch D.M., Ewald B.A., Denholtz M., et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 80 24 (2006) 12009-12016
14. Pinto A.R., Fitzgerald J.C., Giles-Davis W., Gao G.P., Wilson J.M., and Ertl H.C. Induction of CD8 + T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171 12 (2003) 6774-6779
15. Hartman Z.C., Appledorn D.M., Serra D., Glass O., Mendelson T., Clat T., et al. Replication-attenuated Human Adenoviral type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology 374 2 (2008) 453-467
16. Stone D., Ni S., Li Z.Y., Gaggar A., DiPaolo N., Feng Q., et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 79 8 (2005) 5090-5104
17. Appledorn D.M., Kiang A., McBride A., Jiang H., Seregin S., Scott J.M., et al. Wild-type Adenoviruses from groups A-F elicit unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther 15 12 (2008) 885-901
18. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., and Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72 (1998) 926-933
19. Kumar-Singh R., and Chamberlain J.S. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 5 (1996) 913-921
20. Amalfitano A., Begy C.R., and Chamberlain J.S. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA 93 (1996) 3352-3356
21. Hauser M.A., Amalfitano A., Kumar-Singh A., Hauschka S.D., and Chamberlain J.S. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul Disord 7 (1997) 277-283
22. Hu H., Serra D., and Amalfitano A. Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 10 (1999) 355-364
23. Schaack J. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins. Viral Immunol 18 (2005) 79-88
24. Schaack J., Bennett M.L., Colbert J.D., Torres A.V., Clayton G.H., Ornelles D., et al. E1A and E1B proteins inhibit inflammation induced by adenovirus. Proc Natl Acad Sci USA 101 (2004) 3124-3129
25. Corey D.P., García-Añoveros J., Holt J.R., Kwan K.Y., Lin S.Y., Vollrath M.A., et al. TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. Nature 432 (2004) 723-730
26. Luebke A.E., Steiger J.D., Hodges B.L., and Amalfitano A. A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function. Gene Ther 8 (2001) 789-794
27. Everett R.S., Hodges B.L., Ding E.Y., Xu F., Serra D., and Amalfitano A. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 14 (2003) 1715-1726
28. Hodges B.L., Serra D., Hu H., Begy C.A., Chamberlain J.S., and Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2 4 (2000) 250-259
29. Harari A., Vallelian F., Meylan P.R., and Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174 (2005) 1037-1145
30. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 + T cells. Blood 107 (2006) 4781-4789
31. Barouch D.H., and Nabel G.J. Adenovirus vector based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 (2005) 149-156
32. Barouch D.H., Yang Z.Y., Kong W.P., Korioth-Schmitz B., Sumida S.M., Truitt D.M., et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79 (2005) 8828-8834
33. Robinson H.L. New hope for an AIDS vaccine. Nat Rev Immunol 2 (2002) 239-250
34. Jooss K., Yang Y., Fisher K.J., and Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72 (1998) 4212-4223
35. Kirk C.J., Hartigan-O'Connor D., and Mulé J.J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61 (2001) 8794-8802
36. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61 (2001) 2062-2070
37. Kirk C.J., and Mulé J.J. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 11 (2000) 797-806
38. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 (2003) 799-803
39. Harvey B.G., Hackett N.R., El-Sawy T., Rosengart T.K., Hirschowitz E.A., Lieberman M.D., et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 73 (1999) 6729-6742
40. Rahman A., Tsai V., Goudreau A., Shinoda J.Y., Wen S.F., Ramachandra M., et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 3 (2001) 768-778
41. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., and Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6 (1999) 1574-1583
42. Vincent T., Harvey B.G., Hogan S.M., Bailey C.J., Crystal R.G., and Leopold P.L. Rapid assessment of adenovirus serum neutralizing antibody titer based on quantitative, morphometric evaluation of capsid binding and intracellular trafficking: population analysis of adenovirus capsid association with cells is predictive of adenovirus infectivity. J Virol 75 (2001) 1516-1521
43. Nevins J.R. Mechanism of activation of early viral transcription by the adenovirus E1a gene product. Cell 26 (1981) 213-220
44. Nevins J.R., Imperiale M.J., Kao H.T., Strickland S., and Feldman L.T. Detection of an adenovirus E1a-like activity in mammalian cells. Curr Topics Microbiol Immunol 113 (1984) 15-19
45. Yang Y., Ertl H.C., and Wilson J.M. MHC class-I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1 (1994) 433-442
46. Yang Y., Nunes F.A., Berensci K., Furth E.E., Gonczol E., and Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91 (1994) 4407-4411
47. Hartigan-O'Connor D., Barjot C., Salvatori G., and Chamberlain J.S. Generation and growth of gutted adenoviral vectors. Methods Enzymol 346 (2002) 224-246
48. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77 23 (2003) 12764-12772